The Effects of Digital eHealth Versus Onsite 2-Day Group-Based Education in 255 Patients With Irritable Bowel Syndrome: Cohort Study
JMIR Human Factors · 2025
DOI: 10.2196/43618 ↗At a glance
Kohortenstudie in JMIR Human Factors, 2025. Written by Birgitte Berentsen and 5 co-authors. Institution: Department of Clinical Medicine, University of Bergen, Bergen, Norway. Major MEDLINE topics: Irritable Bowel Syndrome, Telemedicine, Patient Education as Topic. Cited 1 times so far (Crossref); 34 references. The full text is freely available in PubMed Central.
Topics: Digitalisierung in der Pflege
Abstract (original language)
Background
Irritable bowel syndrome (IBS) has a high worldwide prevalence and there are few effective treatment options. Patient education can influence patient behavior that subsequently may lead to changes in attitudes and skills necessary for maintenance or improvement in management of symptom severity and quality of life. However, as postdiagnostic patient education can be resource demanding, assessment of digital approaches and verification of their effectiveness is warranted.
Objective
This cohort study aimed to investigate the effects of a digital web-based multidisciplinary eHealth program on the domains of symptom severity (Irritable Bowel Syndrome Symptom Severity Scale [IBS-SSS]), quality of life (irritable bowel syndrome quality of life [IBS-QOL]), anxiety and depression (Hospital Anxiety and Depression Scale), and a measure of general client satisfaction (client satisfaction questionnaire), compared with an onsite multidisciplinary 2-day group-based education program (“IBS-school”), in 2 cohorts of 255 patients with IBS.
Methods
Patients diagnosed with IBS, aged 15-70 years, were enrolled after referral to the Section of Gastroenterology at Haukeland University Hospital, Norway. In total, 132 patients were recruited to the eHealth program and 123 to the IBS-school group for comparison. Data were self-reported and collected digitally at enrollment and after 3 months, between 2017 and 2019. Furthermore, 71 attending the eHealth program and 49 attending the IBS-school completed the questionnaires at 3 months. Intervention response was defined as a reduction of ≥50 points on the IBS-SSS.
Results
Patients attending the eHealth program reported a significant reduction in IBS symptom severity 3 months after treatment (n=71), compared with patients attending the IBS-school (n=50). Overall, patients categorized as intervention responders in both programs showed a significant reduction in symptom severity at 3 months. Here, 41% (29/71) of patients attending the eHealth program reported a mean IBS-SSS reduction of 103 (SD 72.0) points ( P
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Clinical Medicine, University of Bergen, Bergen, Norway.
- Department of Medicine, National Center for Functional Gastrointestinal Disorders, Haukeland University Hospital, Bergen, Norway.
ORCID profiles: Birgitte Berentsen, Camilla Thuen, Eline Margrete Randulff Hillestad, Elisabeth Kjelsvik Steinsvik, Trygve Hausken, Jan Gunnar Hatlebakk
Cite
APA
Berentsen, B., Thuen, C., Hillestad, E. M. R., Steinsvik, E. K., Hausken, T., & Hatlebakk, J. G. (2025). The Effects of Digital eHealth Versus Onsite 2-Day Group-Based Education in 255 Patients With Irritable Bowel Syndrome: Cohort Study. JMIR Human Factors. https://doi.org/10.2196/43618
Vancouver
Berentsen B, Thuen C, Hillestad EMR, Steinsvik EK, Hausken T, Hatlebakk JG. The Effects of Digital eHealth Versus Onsite 2-Day Group-Based Education in 255 Patients With Irritable Bowel Syndrome: Cohort Study. JMIR Human Factors. 2025. doi:10.2196/43618
BibTeX
@article{Berentsen2025,
author = {Berentsen, Birgitte and Thuen, Camilla and Hillestad, Eline Margrete Randulff and Steinsvik, Elisabeth Kjelsvik and Hausken, Trygve and Hatlebakk, Jan Gunnar},
title = {The Effects of Digital eHealth Versus Onsite 2-Day Group-Based Education in 255 Patients With Irritable Bowel Syndrome: Cohort Study},
journal = {JMIR Human Factors},
year = {2025},
doi = {10.2196/43618}
}
EUVIMED